News >

Novel Strategies Progress Through mCRC Pipeline

Ellie Leick
Published: Tuesday, Nov 05, 2019

Ryan B. Corcoran, MD, PhD

Ryan B. Corcoran, MD, PhD

Several late-stage therapies, including targeted agents and immunotherapies, are being evaluated for patients with relapsed/refractory colorectal cancer (CRC) who have progressed on first- and second-line therapies, explained Ryan B. Corcoran, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication